The Lancet Oncology· Dan Liu, Zikun Peng, Wei Zhang, Cui Feng, Ping Wang, Jundong Li, Yuanjia Wen, Wanying Shan, Yu Xia, Huayi Li, Bingquan Li, Ronghua Liu, Mingfu Wu, Zhen Li, Rong Liu, Gang Chen, Ya Wang, Xiaofei Jiao, Xiao Li, Cheng Liu, Rutie Yin, Shengtao Zhou, Maomao Li, Zhifeng Xia, Yu Dong, Shanyang He, Yi Huang, COCPO Consortium, Kun Song, Li Hong, Ding Ma, Yong Fang, Qinglei Gao·· 2026-10-08AI 评分53
尼拉帕利单药新辅助治疗在HRD阳性晚期卵巢癌中的II期单臂试验
[Articles] Neoadjuvant niraparib monotherapy for unresectable, homologous recombination deficiency-positive, high-grade serous ovarian cancer (NANT): a multicentre, single-arm, phase 2 trial
AI 导读
尼拉帕利单药新辅助治疗在HRD阳性晚期卵巢癌患者中显示抗肿瘤活性并实现R0切除。该试验为单臂II期研究,需通过随机对照试验验证其疗效与安全性。
来源:The Lancet Oncology · thelancet.com